Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP299871.RAW4kGe6VCWpFCzKYYe4zeMCP3o5iR_quEBJkv04uzSS4130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP299871.RAW4kGe6VCWpFCzKYYe4zeMCP3o5iR_quEBJkv04uzSS4130_provenance.
• NP756190.RAhCOGLlfykzjPXsjFEZgh0bej5JT19zPKNkP640Klx9I130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756190.RAhCOGLlfykzjPXsjFEZgh0bej5JT19zPKNkP640Klx9I130_provenance.
• NP301972.RA1p8jn0xcjS8IYX9YZaBT8EMxNKbMopAUpTruscaZY3Y130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP301972.RA1p8jn0xcjS8IYX9YZaBT8EMxNKbMopAUpTruscaZY3Y130_provenance.
• NP584577.RA3srm_5tzoSzY08fb4wV3cAsos2s9-AJIdxzOfuBQhAc130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP584577.RA3srm_5tzoSzY08fb4wV3cAsos2s9-AJIdxzOfuBQhAc130_provenance.
• NP622764.RAexu7SiR5HGKLrAcRni-XDD5JYKhOoyMKwv6qQSgBAV0130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622764.RAexu7SiR5HGKLrAcRni-XDD5JYKhOoyMKwv6qQSgBAV0130_provenance.
• assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP776164.RAWQUUDtFAcodSgnWuTc2PIrS-s_1oIZRwFb3BJpVdgxs130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776164.RAWQUUDtFAcodSgnWuTc2PIrS-s_1oIZRwFb3BJpVdgxs130_provenance.
• NP776168.RAROSKIkyRT7WaXVpv-OmnFSq2_k94yLEQ_Pd2fpiDb5Q130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776168.RAROSKIkyRT7WaXVpv-OmnFSq2_k94yLEQ_Pd2fpiDb5Q130_provenance.
• NP776171.RAanJXfMoNT-6ACWE0ldxlH7jBVJw_u-6FrnQND11yF9Y130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776171.RAanJXfMoNT-6ACWE0ldxlH7jBVJw_u-6FrnQND11yF9Y130_provenance.
• NP621440.RAnm6sdy3HTszSc8_nCy50e6sl6RdcKR2xoSX2xlxsdxc130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621440.RAnm6sdy3HTszSc8_nCy50e6sl6RdcKR2xoSX2xlxsdxc130_provenance.
• NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.
• NP885452.RAFGFAc-kadYitdX9FE17W9TxHDRn4GfYRVOtfXLfYDmU130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885452.RAFGFAc-kadYitdX9FE17W9TxHDRn4GfYRVOtfXLfYDmU130_provenance.
• NP624080.RAKDh-A9rjeZl5lwG-59y-KTvMfcRbomBEFB9aGCSDV7s130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624080.RAKDh-A9rjeZl5lwG-59y-KTvMfcRbomBEFB9aGCSDV7s130_provenance.
• NP776163.RA8PUrPHJSiaQ7BOxp9E0MWHs95LK-y9VFB1WncgPzIQA130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776163.RA8PUrPHJSiaQ7BOxp9E0MWHs95LK-y9VFB1WncgPzIQA130_provenance.